Burning Rock Biotech Limited (BNR)

Market Cap	101.67M +236.0%
Revenue (ttm)	77.14M +4.6%
Net Income	-7.91M
EPS	-0.74
Shares Out	10.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,933
Open	8.46
Previous Close	8.73
Day's Range	8.40 - 10.25
52-Week Range	2.80 - 41.72
Beta	1.32
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 16, 2026

About BNR

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cance...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 667
• Stock Exchange: NASDAQ
• Ticker Symbol: BNR
• Website: https://www.brbiotech.com

Financial Performance

In 2025, Burning Rock Biotech's revenue was 539.57 million, an increase of 4.60% compared to the previous year's 515.82 million. Losses were -55.35 million, -84.03% less than in 2024.

Financial numbers in CNY